Last reviewed · How we verify
LentiGlobin BB305 Drug Product — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
LentiGlobin BB305 Drug Product (LentiGlobin BB305 Drug Product) — Genetix Biotherapeutics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LentiGlobin BB305 Drug Product TARGET | LentiGlobin BB305 Drug Product | Genetix Biotherapeutics Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LentiGlobin BB305 Drug Product CI watch — RSS
- LentiGlobin BB305 Drug Product CI watch — Atom
- LentiGlobin BB305 Drug Product CI watch — JSON
- LentiGlobin BB305 Drug Product alone — RSS
Cite this brief
Drug Landscape (2026). LentiGlobin BB305 Drug Product — Competitive Intelligence Brief. https://druglandscape.com/ci/lentiglobin-bb305-drug-product. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab